Seoulin Bioscience Co.Ltd (038070) — Cash Flow Quality Index
Seoulin Bioscience Co.Ltd (038070) has a Cash Flow Quality Index of 3.62x as of September 2025. Operating cash flow of ₩2.78 Billion exceeds net income of ₩766.93 Million, indicating high earnings quality where cash backs reported profits. Explore 038070 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Seoulin Bioscience Co.Ltd Cash Flow Quality Index (2013–2025)
Historical Cash Flow Quality Index for Seoulin Bioscience Co.Ltd across 12 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see Seoulin Bioscience Co.Ltd cash flow conversion.
Annual Cash Flow Quality Index for Seoulin Bioscience Co.Ltd (2013–2025)
Year-by-year earnings quality comparison for Seoulin Bioscience Co.Ltd.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 6.50x | ₩4.76 Billion | ₩731.98 Million | ▲ +542.8% |
| 2024 | -1.47x | ₩-4.61 Billion | ₩3.14 Billion | ▼ -221.7% |
| 2022 | -0.46x | ₩-4.36 Billion | ₩9.54 Billion | ▼ -179.8% |
| 2021 | 0.57x | ₩8.92 Billion | ₩15.59 Billion | ▼ -24.0% |
| 2020 | 0.75x | ₩3.68 Billion | ₩4.89 Billion | ▼ -8.6% |
| 2019 | 0.82x | ₩7.32 Billion | ₩8.88 Billion | ▼ -48.2% |
| 2018 | 1.59x | ₩4.17 Billion | ₩2.62 Billion | ▲ +151.9% |
| 2017 | 0.63x | ₩1.30 Billion | ₩2.06 Billion | ▼ -4.7% |
| 2016 | 0.66x | ₩2.76 Billion | ₩4.16 Billion | ▼ -70.6% |
| 2015 | 2.26x | ₩4.12 Billion | ₩1.83 Billion | ▲ +119.7% |
| 2014 | 1.03x | ₩2.74 Billion | ₩2.67 Billion | ▼ -13.5% |
| 2013 | 1.19x | ₩4.94 Billion | ₩4.16 Billion | — |